(Q34133579)

31 July 2017

1 reference

title

Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities (English)

1 reference

31 July 2017

Butera ST

1

1 reference

31 July 2017

1 December 2000

1 reference

31 July 2017

1 reference

31 July 2017

48

1 reference

31 July 2017

3

1 reference

31 July 2017

143-176

1 reference

Additive effects of IL-2 and protein kinase A type I antagonist on function of T cells from HIV-infected patients on HAART.

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Restoration of immune response by a cationic amphiphilic drug (AY 9944) in vitro: a new approach To chemotherapy against human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Human immunodeficiency virus induces a dual regulation of Bcl-2, resulting in persistent infection of CD4(+) T- or monocytic cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Effects of subcutaneous interleukin-2 therapy on phenotype and function of peripheral blood mononuclear cells in human immunodeficiency virus infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Induction of HIV-1 replication by type 1-like cytokines, interleukin (IL)-12 and IL-15: effect on viral transcriptional activation, cellular proliferation, and endogenous cytokine production

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of cytokine-driven human immunodeficiency virus type 1 replication by protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Early reduction of immune activation in lymphoid tissue following highly active HIV therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

NF-kappa B-dependent and -independent pathways of HIV activation in a chronically infected T cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Restoration of the immune system with anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Cellular factors as alternative targets for inhibition of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

CD14 is involved in control of human immunodeficiency virus type 1 expression in latently infected cells by lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Primary CD8+ cells from HIV-infected individuals can suppress productive infection of macrophages independent of beta-chemokines

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Mechanisms of HIV-1 latency

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of HIV-1 replication by combination of a novel inhibitor of TNF-alpha with AZT.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Cytokines from vaccine-induced HIV-1 specific cytotoxic T lymphocytes: effects on viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Blocking of Tat-dependent HIV-1 RNA modification by an inhibitor of RNA polymerase II processivity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV-1 Reactivation in Resting Peripheral Blood Mononuclear Cells of Infected Adults Upon in Vitro CD4 Cross-Linking by Ligands of the CDR2-Loop in Extracellular Domain 1

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Few infected CD4+ T cells but a high proportion of replication-competent provirus copies in asymptomatic human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Active nuclear import of human immunodeficiency virus type 1 preintegration complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Cytokine involvement in viral permissiveness and the progression of HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Application of latent HIV-1 infected cellular models to therapeutic intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Compounds that target novel cellular components involved in HIV-1 transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Analysis of human immunodeficiency virus in semen: indications of a genetically distinct virus reservoir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

During HIV-1 infection most blood dendritic cells are not productively infected and can induce allogeneic CD4+ T cells clonal expansion

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Highly purified CD25- resting T cells cannot be infected de novo with HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Latent reservoirs of HIV: obstacles to the eradication of virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Re-emergence of HIV after stopping therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

The critical role of p38 MAP kinase in T cell HIV-1 replication.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of HIV activation in latently infected cells by flavonoid compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Casein kinase II is a selective target of HIV-1 transcriptional inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Isoquinolinesulphonamide derivatives inhibit transcriptional elongation of human immunodeficiency virus type 1 RNA in a promyelocytic model of latency

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Highly active antiretroviral therapy normalizes the function of progenitor cells in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Binding of NF-kB to the HIV-1 LTR is not sufficient to induce HIV-1 LTR activity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Tat and rev differentially affect restricted replication of human immunodeficiency virus type 1 in various cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Viral dynamics in HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Generation of endogenous tumour necrosis factor-alpha in MOLT-4 cells during the acute replication phase of human immunodeficiency virus type 1 determines the subsequent latent infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Acridone derivatives are selective inhibitors of HIV-1 replication in chronically infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Molecular basis of latency in pathogenic human viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Cellular transcription factors involved in the regulation of HIV-1 gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

The in vitro induction of human immunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall antigen response to Mycobacterium tuberculosis is the result of a balance of the effects of endogenous in

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Therapeutic vaccines in HIV.1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Interleukin 1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin 1 receptor antagonist and tumor necrosis factor binding protein type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Activation of HIV gene expression during monocyte differentiation by induction of NF-kB

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Multiple modes of cellular activation and virus transmission in HIV infection: a role for chronically and latently infected cells in sustaining viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Ongoing HIV dissemination during HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Heat shock induces HIV-1 replication in chronically infected promyelocyte cell line OM10.1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Follicular dendritic cells and human immunodeficiency virus infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

CCAAT/enhancer binding protein (C/EBP) sites are required for HIV-1 replication in primary macrophages but not CD4(+) T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Lymphocyte kinetics and precursor frequency-dependent recovery of CD4(+)CD45RA(+)CD62L(+) naive T cells following triple-drug therapy for HIV type 1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV-1 RNA levels in cerebrospinal fluid and plasma correlate with AIDS dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of HIV type 1 replication in chronically infected monocytes and lymphocytes by retrovirus-mediated gene transfer of anti-Rev single-chain variable fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Germinal centre CD4+ T cells are an important site of HIV replication in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Recombinant human IL-16 inhibits HIV-1 replication and protects against activation-induced cell death (AICD)

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

AIDS pathogenesis: the role of accessory gene mutations, leading to formation of long-lived persistently infected cells and/or apoptosis-inducing HIV-1 particles.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Doxorubicin inhibits Tat-dependent transactivation of HIV type 1 LTR.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Taking a new TAK on tat transactivation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Mutational analysis of human immunodeficiency virus type 1 (HIV-1) accessory genes: requirement of a site in the nef gene for HIV-1 replication in activated CD4+ T cells in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Naturally occurring accessory gene mutations lead to persistent human immunodeficiency virus type 1 infection of CD4-positive T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of NF-kappa B by sodium salicylate and aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Human immunodeficiency virus type 1 dynamics in different lymphoid tissue compartments

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Membrane tumor necrosis factor (TNF) induced cooperative signaling of TNFR60 and TNFR80 favors induction of cell death rather than virus production in HIV-infected T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

T cell-derived suppressive activity: evidence of autocrine noncytolytic control of HIV type 1 transcription and replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV-1 DNA and mRNA concentrations are similar in peripheral blood monocytes and alveolar macrophages in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Derivation of herpesvirus saimiri-transformed CD8+ T cell lines with noncytotoxic anti-HIV activity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

CD8(+) cell noncytotoxic anti-human immunodeficiency virus response inhibits expression of viral RNA but not reverse transcription or provirus integration

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Productive infection of double-negative T cells with HIV in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Viral latency in HIV disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

In vivo estimates of division and death rates of human T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intr

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of HIV-1 replication and NF-kappa B activity by cysteine and cysteine derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Negative regulation of human immune deficiency virus replication in monocytes. Distinctions between restricted and latent expression in THP-1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

CD8+ T-cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta, suppress HIV-1 replication in monocyte/macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Factors secreted by human T lymphotropic virus type I (HTLV-I)-infected cells can enhance or inhibit replication of HIV-1 in HTLV-I-uninfected cells: implications for in vivo coinfection with HTLV-I and HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

In vitro reactivation of human immunodeficiency virus 1 from latently infected, resting CD4+ T cells after bacterial stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

9-Nitrocamptothecin inhibits tumor recrosis factor-mediated activation of human immunodeficiency virus type 1 and enhances apoptosis in a latently infected T cell clone

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Replication of human immunodeficiency virus-1 in primary human T cells is dependent on the autocrine secretion of tumor necrosis factor through the control of nuclear factor-kappa B activation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of replication of reactivated human immunodeficiency virus type 1 (HIV-1) in latently infected U1 cells transduced with an HIV-1 long terminal repeat-driven PKR cDNA construct

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Induction of CD4 expression and human immunodeficiency virus type 1 replication by mutants of the interferon-inducible protein kinase PKR.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

In vitro separation and expansion of CD4 lymphocytes from HIV-infected individuals without activation of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Effect of granulocyte colony-stimulating factor (G-CSF) in human immunodeficiency virus-infected patients: increase in numbers of naive CD4 cells and CD34 cells makes G-CSF a candidate for use in gene therapy or to support antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Macrophages as a source of HIV during opportunistic infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

How immune-based interventions can change HIV therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Lymphoid organs function as major reservoirs for human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Decay characteristics of HIV-1-infected compartments during combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Transforming growth factor beta suppresses human immunodeficiency virus expression and replication in infected cells of the monocyte/macrophage lineage

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Gö 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Interleukin-10 enhances tumor necrosis factor-alpha activation of HIV-1 transcription in latently infected T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Activated B lymphocytes from human immunodeficiency virus-infected individuals induce virus expression in infected T cells and a promonocytic cell line, U1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Naïve and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation: implicatip6s for transmission and pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

N-acetylcysteine inhibits latent HIV expression in chronically infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Correlates of latent and productive HIV type-1 infection in tonsillar CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

CD8+ T cells from HIV type 1-seronegative individuals suppress virus replication in acutely infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Induction of monocytic differentiation and NF-kappa B-like activities by human immunodeficiency virus 1 infection of myelomonoblastic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Megalomicin inhibits HIV-1 replication and interferes with gp160 processing

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication by a bioavailable serine/threonine kinase inhibitor, fasudil hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV load in highly purified CD8+ T cells retrieved from pulmonary and blood compartments

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Role of p38 mitogen-activated protein kinase in HIV type 1 production in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Interleukin 18 stimulates HIV type 1 in monocytic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Engagement of adhesion molecules (CD18, CD11a, CD45, CD44, and CD58) enhances human immunodeficiency virus type 1 replication in monocytic cells through a tumor necrosis factor-modulated pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Rates of shutdown of HIV-1 into latency: roles of the LTR and tat/rev/vpu gene region

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Activation of virus replication after vaccination of HIV-1-infected individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Asymptomatic HIV infection is characterized by rapid turnover of HIV RNA in plasma and lymph nodes but not of latently infected lymph-node CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Expression of the c-myc proto-oncogene is essential for HIV-1 infection in activated T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Cyclosporins: immunosuppressive drugs with anti-HIV-1 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Activation of latent HIV-1 by Mycobacterium tuberculosis and its purified protein derivative in alveolar macrophages from HIV-infected individuals in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Persistent productive HIV infection in EBV-transformed B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Anti-rheumatic compound aurothioglucose inhibits tumor necrosis factor-alpha-induced HIV-1 replication in latently infected OM10.1 and Ach2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Interleukin-16 inhibits human immunodeficiency virus type 1 entry and replication in macrophages and in dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

IL-16 anti-HIV-1 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Hexamethylene bisacetamide activates the human immunodeficiency virus type 1 provirus by an NF-kappa B-independent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Tumour necrosis factors (alpha, beta) induced by HIV-1 in peripheral blood mononuclear cells potentiate virus replication.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Immune stimulation and HIV-1 viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

CD7 expression distinguishes subsets of CD4(+) T cells with distinct functional properties and ability to support replication of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Interleukin 10 blocks HIV replication in macrophages by inhibiting the autocrine loop of tumor necrosis factor alpha and interleukin 6 induction of virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Cytokine regulation of HIV replication induced by dendritic cell-CD4-positive T cell interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV-1 latency due to the site of proviral integration

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Productive infection of neonatal CD8+ T lymphocytes by HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4+ T Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: inhibition of mRNA expression

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900133-9

7 January 2021

10.1016/S0166-3542(00)00133-9

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11164503